Abstract
There are several new chemotherapeutic agents that, as their combinations, are particularly active in advanced disease and should be considered in trials of adjuvant therapies of minimal residual disease (MRD).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Anderson, T., McMenamin, M. G., Schein, P. S.: Chlorozotocin, [2-(3-2-)3-(2-chloroethyl)-3-nitrosoureido γ-D-glycopyranose], an antitumor agent with modified bone marrow toxicity. Cancer Res. 35, 761–765 (1975).
Dantchev, D., Paintrand, M., Hayat, M., Umezawa, H., Muggia, G., Mathé, G.: Electron microscopy on Golden hamster of compared cardiotoxicity of several anthracyclines. (In preparation) (1978).
Djerassi, I.: High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: background and rationale, Part 3. Cancer Chemother. Rep. 6 3-6 (1975).
EORTC Clinical Screening Group: A phase II clinical trial of peptichemio. Biomedicine 27, 290–294 (1977).
EORTC Clinical Screening Group: A phase II clinical trial of cytembena. Biomedicine 26, 392–395 (1977).
Florentin, I., Mathé, G.: Comparative experimental immunopharmacology of three nitrosoureas: RFCNU, RPCNU and chlorozotocin. (In preparation) (1978).
Gralla, R. J., Young, C. W.: A phase II trial on vindesine in nonsmall cell carcinoma of the lung. International Workshop on Vindesine. Frankfurt, 7. July 1978.
Hayat, M., Mathé, G.: Comparative experimental oncostatic pharmacoly of three nitrosoureas: RFCNU, RPCNU and chlorozotocin. (In preparation) (1978).
Hayat, M., Brule, G., Clavel, B., Chauvergne, J., Cappelaere, P., Cattan, A., Guerrin, J., Pommatau, E., Bayssas, M., Gouveia, J., Mathé, G.: Essai thérapeutique clinique phase II du cisplatinum. Nouv. Presse Méd. (1978) (in press).
Imbach, J. L., Montero, J. L., Moruzzi, A., Serrou, B., Chenu, E., Hayat, M., Mathé, G.: The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. Biomedicine 23, 410–413 (1975).
Jasmin, C., Mathé, G.: Comparative experimental hematopharmacology of three nitrosoureas: RFCNU, RPCNU and chlorozotocin. (In preparation) (1978).
Mathé, G., Serrou, B., Hayat, M., De Vassal, F., Misset, J. L., Schwarzenberg, L., Machover, D., Ribaud, P., Belpomme, D., Jasmin, C., Musset, M., Montero, J. L., Imbach, J. L.: Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative in digestive tract tumours. Biomedicine 27, 294–297 (1977).
Mathé, G., Bayssas, M., De Vassal, F., Gouveia, J.: Phase II trials of three oncostatic nitrosoureas: RFCNU, RPCNU and chlorozotocin. (In preparation) (1978).
Mathé, G., Misset, J. L., De Vassal, F., Hayat, M., Gouveia, J., Machover, D., Belpomme, D., Schwarzenberg, L., Ribaud, P., Pico, J. L., Musset, M., Jasmin, C., De Luca, L.: Traitement de leucémies et hématosarcomes par la vindésine. Résultats d’un essai phase II en termes d’induction de rémission. Nouv. Presse Méd. 7, 525–528 (1978).
Mathé, G., Misset, J. L., De Vassal, F., Gouveia, J., Hayat, M., Machover, D., Belpomme, D., Pico, J. L., Schwarzenberg, L., Ribaud, P., Musset, M., Jasmin, C., De Luca, L.: Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin’s disease: absence of cross-resistance with vincristine. Cancer Treat. Rep. 62, 805–809 (1978).
Mathé, G., Misset, J. L., Bayssas, M., Gouveia, J., De Vassal, F., Hayat, M., Delgado, M., Gil, M. A., Machover, D.: Does adriamycin increases survival in metastatic breast patients? Preliminary evaluation. Cancer Chemother. Pharmacol. (1978) (in press).
Mathé, G., Bayssas, M., Gouveia, J., De Vassal, F., Dantchev, D.: A propos de la Revue Générale de Jacquillat et al.: l’aclacynomyciine, une nouvelle anthracycline non alopéciante et moins cardiotoxique que l’adriamycine. Nouv. Presse Méd. (1978) (in press).
Misset, J. L., De Vassal, F., Hayat, M., Machover, D., Belpomme, D., Schwarzenberg, L., Ribaud, P., Musset, M., Jasmin, C., Mathé, G.: Phase II clinical trial with vindesine for remission induction in acute leukaemia, blastic crisis of chronic myeloid leukaemia, lymphosarcoma and Hodgkin’s disease. Absence of cross resistance with vincristine. Med. Oncol. 3, S21 (1977).
Powles, T., Smith, I. E.: Vindesine in the treatment of breast cancer. International Workshop on Vindesine. Frankfurt, 7. July 1978.
Retsas, S., Newton, K. A., Westbury, G.: Vindesine in treatment of advanced malignant melanoma. International Workshop on Vindesine. Frankfurt, 7. July 1978.
Schwarzenberg, L., Mathé, G., Hayat, M., De Vassal, F., Amiel, J. L., Cattan, A., Schneider, M., Schlumberger, J. R., Jasmin, C., Ngo Minh Man: Une nouvelle combinaison de méthotrexate-acide folinique pour le traitement des cancers (leucémies et tumeurs solides). Presse Méd. 77, 385 (1969).
Serrou, B., Imbach, J. L., Hayat, M., Mathé, G., Macieira-Coelho, A. M.: Experimental screening and pharmacology of new sugar derivatives of nitrosourea. Proc. Am. Assoc. Cancer Res. 18, 223 (Abs. 892) (1977).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Mathé, G. et al. (1979). Some New Chemotherapeutic Agents and Combinations Possibly Available for New Adjuvant Therapies of Minimal Disease. In: Bonadonna, G., Mathé, G., Salmon, S.E. (eds) Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. Recent Results in Cancer Research, vol 68. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81332-0_65
Download citation
DOI: https://doi.org/10.1007/978-3-642-81332-0_65
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81334-4
Online ISBN: 978-3-642-81332-0
eBook Packages: Springer Book Archive